Exozymes (EXOZ) Total Non-Current Liabilities (2023 - 2026)
Exozymes (EXOZ) posted quarterly Total Non-Current Liabilities of -$343453.0 for Q4 2025, up 87.53% quarter-over-quarter from -$2.8 million in Q3 2025.
Exozymes (EXOZ) Total Non-Current Liabilities (2023 - 2026) Analysis & Trends
Exozymes (EXOZ) has reported Total Non-Current Liabilities for 3 consecutive years, with -$343453.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Total Non-Current Liabilities changed N/A year-over-year to -$343453.0; the TTM figure through Dec 2025 stood at -$343453.0 (changed N/A YoY), while the FY2025 annual figure was -$343453.0, changed N/A from the prior year.
- Total Non-Current Liabilities grew to -$343453.0 in Q4 2025 per EXOZ's latest filing, from -$2.8 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $6.2 million in Q3 2024 and bottomed at -$5.5 million in Q1 2025.
- Historically, Total Non-Current Liabilities has averaged -$675511.2 across 3 years, with a median of -$1.5 million in 2025.
- On a YoY basis, Total Non-Current Liabilities climbed as much as 144.7% in 2025 and fell as far as 144.7% in 2025.
- Exozymes' Total Non-Current Liabilities stood at $2.9 million in 2023, then soared by 109.38% to $6.2 million in 2024, then tumbled by 105.57% to -$343453.0 in 2025.
- Business Quant data shows EXOZ's Total Non-Current Liabilities at -$343453.0 in Q4 2025, -$2.8 million in Q3 2025, and -$4.5 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | Exozymes | 62.35 Mn | 62.35 Mn | - | 2.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.43 Mn |
| Dec 31, 2025 | -343,453.00 |
| Sep 30, 2025 | -2.75 Mn |
| Jun 30, 2025 | -4.54 Mn |
| Mar 31, 2025 | -5.52 Mn |
| Sep 30, 2024 | 6.16 Mn |
| Dec 31, 2023 | 2.94 Mn |